Ameriprise’s Contineum Therapeutics CTNM Stock Holding History

Ameriprise’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-209,633	Closed	-$2.4M	–	4239
2025 Q4	$2.4M	Buy	+209,633	New	+$2.39M	﹤0.01%	2905

Other funds holding CTNM

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ameriprise's CTNM Position: Q1 2026 in Review

Ameriprise sold out of Contineum Therapeutics (CTNM) in Q1 2026, closing a stake of 209,633 shares — an estimated $2.4M sold.

Ameriprise first reported a position in CTNM in Q4 2025 and held it in 1 quarter. The position peaked at $2.4M in Q4 2025. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

Ameriprise reported no remaining Contineum Therapeutics position as of Q1 2026 after selling out during the quarter.
Ameriprise sold 209,633 Contineum Therapeutics shares in Q1 2026, an estimated $2.4M.
Ameriprise first reported a position in Contineum Therapeutics in Q4 2025 and held it in 1 quarter.
Ameriprise's Contineum Therapeutics position peaked at $2.4M in Q4 2025.
90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.